Nationwide Real-World Outcomes of Trial Eligible and Trial Ineligible Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab
This is the first nationwide real-world study evaluating NIVO/IPI outcomes in unselected mRCC. Trial-eligible patients achieved survival outcomes comparable to clinical trial results. Although ineligible patients derived less benefit, they still experienced meaningful clinical outcomes. These findings provide benchmark data for treatment of real-world mRCC populations in routine clinical practice.
Authors
- Kasper Madsen (ORCID: https://orcid.org/0009-0006-7612-3906)
- Morten Andersen (ORCID: https://orcid.org/0000-0001-7029-2860)
- Ane B. Iversen (ORCID: https://orcid.org/0009-0000-9529-4870)
- Niels Fristrup (ORCID: https://orcid.org/0009-0006-4442-0535)
- Jon Røikjær Henriksen (ORCID: https://orcid.org/0000-0002-2905-5342)
- Jesper Andreas Palshof (ORCID: https://orcid.org/0000-0001-5412-9246)
- Inge Marie Svane (ORCID: https://orcid.org/0000-0002-9451-6037)
- Mette Syberg Jespersen (ORCID: https://orcid.org/0000-0002-9361-0945)
- A. Darras
- Sarah Grønbech Steen
- Niels Viggo Jensen (ORCID: https://orcid.org/0000-0002-3812-7993)
Institutions
- University of Copenhagen (DK)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- IT University of Copenhagen (DK)
Publication Details
- Journal
- Clinical Genitourinary Cancer
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1016/j.clgc.2025.102450
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52